TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06637150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpicilib
Description: Dalpicilib 100 mg once daily from day 1 to day 21, every 4 weeks, for a total of 3 years, in combination with endocrine therapy for 5 years.
Study: NCT05693831

Intervention type: OTHER
Intervention: Cellworks Report
Description: Survey physicians and molecular tumor board perspectives of the benefit of Cellworks Singula™ and Ventura™ reports in facilitating treatment decisions in pan-cancer patients.

Intervention type: OTHER
Intervention: Cellworks Report
Description: Survey physicians and molecular tumor board perspectives of the benefit of Cellworks Singula™ and Ventura™ reports in facilitating treatment decisions in pan-cancer patients.
Study: NCT05911087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phase II:SWIM816;SARS-Cov-2;
Description: The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase II:SW-BIC-213;SARS-Cov-2;
Description: The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PhaseIII:SWIM816;SARS-Cov-2;
Description: The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2；
Description: The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)
Study: NCT04871009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback Intervention
Description: InteraXon, Inc. produces the MUSE 2 wearable neurofeedback device and mobile application (heretofore referred to as the MUSE app), respectively comprising the electroencephalogram (EEG) hardware and interactive software components that will be used in this intervention. The MUSE 2 is an adjustable headband that is placed across the forehead and over and behind the ears. It contains EEG sensors for active sites across the forehead and behind the ears, and an additional reference site behind the ear. These sensors use EEG technology to passively record children's brainwaves. During a session, caregivers will help children place the MUSE 2 on their heads and connect it to the app on their personal device. Children's brain activity is recorded by the MUSE 2 and is represented on the app through audio-based feedback that children will listen to with earbuds, and use their volition to influence in real time, with the goal of gaining increased control over their own brain activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard of care
Description: trauma focused cognitive behavioral therapy or other behavioral therapy at the discretion of therapist

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: trauma focused cognitive behavioral therapy or other behavioral therapy at the discretion of therapist
Study: NCT06637150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endocrine therapy
Description: standard endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocrine therapy
Description: standard endocrine therapy
Study: NCT06644248

Intervention type: DIAGNOSTIC_TEST
Intervention: Colposcopy
Description: The intervention involves the use of colposcopy, a diagnostic procedure to visually examine the cervix using a colposcope. The procedure includes the application of saline, acetic acid, and iodine solutions to enhance the visualization of cervical tissues and identify abnormalities. The dosage form includes applying these solutions directly to the cervical area. The frequency of the intervention is typically a single session per patient, with the duration of the procedure lasting approximately 10-15 minutes. This study aims to utilize an AI model to analyze the colposcopic images obtained during the procedure to improve the accuracy and efficiency of cervical cancer detection.
Study: NCT06643923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: F (Frequency): 3 days per week, with a total of 24 sessions. I (Intensity): Low to moderate intensity exercises with progression, ensuring no fatigue is induced.~T (Time): Each session will last 30 minutes, over a total period of 8 weeks.~T (Type):~Warm-up exercises Core stabilization exercises: Aimed at improving core stability. Cool-down exercises E (Enjoyment): Gamified exercises, with sessions conducted to music. A (Adherence): A follow-up system will be implemented, including reminder notes and regular sending of session links to ensure compliance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Urotherapy
Description: The urotherapy education program was developed by an expert physiotherapist and was piloted with the families of children with DMD (16 parents) prior to the study. Pre-test and post-test assessments demonstrated that the knowledge level of DMD families increased after the training. Additionally, results from the satisfaction survey indicated a high level of satisfaction among the families regarding the urotherapy education (Mean satisfaction score: 33.875/35.000, Minimum=28, Maximum=35). Therefore, it was deemed appropriate to deliver the same urotherapy presentation to the DMD families within the scope of this study. The training lasts approximately 1 hour and will be delivered to families via an online method. Each family will receive the education individually, and no group sessions will be conducted.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urotherapy
Description: The urotherapy education program was developed by an expert physiotherapist and was piloted with the families of children with DMD (16 parents) prior to the study. Pre-test and post-test assessments demonstrated that the knowledge level of DMD families increased after the training. Additionally, results from the satisfaction survey indicated a high level of satisfaction among the families regarding the urotherapy education (Mean satisfaction score: 33.875/35.000, Minimum=28, Maximum=35). Therefore, it was deemed appropriate to deliver the same urotherapy presentation to the DMD families within the scope of this study. The training lasts approximately 1 hour and will be delivered to families via an online method. Each family will receive the education individually, and no group sessions will be conducted.
Study: NCT06454916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Small Bowel Anastomosis with Flexagon SFM Device with OTOLoc
Description: This study will investigate one type of intervention: small bowel anastomosis creation in subjects undergoing laparoscopic small bowel surgery. Flexagon SFMs and OTOLoc devices will be delivered laparoscopically into two different sections of small bowel that are intended to be anastomosed. An OTOLoc device will be deployed into the small bowel wall in one section of the small bowel to provide access for the deployment of a Flexagon SFM into that section of bowel. The process is repeated at the second section of bowel. Once deployed, the Flexagon SFMs are approximated and positioned, after which the SFMs are couple together to form the anastomosis, with the OTOLoc devices allowing fluidic communication between the two sections of bowel until the anastomosis is fully formed.
Study: NCT05208762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-08046054
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-08046054
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg once every 3 weeks given into the vein (IV; intravenously)
Study: NCT03240211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Pralatrexate 20 or 30 mg/m2 IV push

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Pralatrexate 20 or 30 mg/m2 IV push

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 10 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 10 mg/m2
Study: NCT05480787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam 0.1mg/kg/h
Description: Remimazolam Tosilate for Injection(36mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam 0.3mg/kg/h
Description: Remimazolam Tosilate for Injection(36mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam 0.5mg/kg/h
Description: Remimazolam Tosilate for Injection(36mg)
Study: NCT04806932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The modified approach
Description: The first three attempts via the modified approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: The conventional approach
Description: The conventional approach
Study: NCT06034847

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rescue mechanical thrombectomy in distal vessels
Description: In addition to mechanical thrombectomy in proximal large vessels, mechanical thrombectomy in distal vessels with small stent retrievers combined or not with contact aspiration, or intra-arterial perfusion of thrombolytics such as tPA or uPA or tenecpeplase
Study: NCT05485454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aria Health Aria Free
Description: An in-clinic therapy session with the Aria Free for a duration of 30 minutes under the direct supervision of the Principal Investigator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A Traditional PCD
Description: An in-clinic therapy session with the traditional PCD for a duration of 30 minutes under the direct supervision of the Principal Investigator.
Study: NCT04619927

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Direct CYP2C19 genotyping
Description: CYP2C19 genotype will be determined by the Spartan RX CYP2C19 point-of-care system.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C19 genotyping at the end of the study
Description: Blood-based CYP2C19 genotyping will be performed at the end of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poor metabolisers
Description: Acetylsalicylic acid 100mg once daily plus rivaroxaban 2.5mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermediate metabolisers
Description: Clopidogrel 75mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal metabolisers and unknown metaboliser state
Description: Clopidogrel 75mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal metabolisers and unknown metaboliser state
Description: Clopidogrel 75mg once daily
Study: NCT04265053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 MG/50 MG
Description: Indomethacin is a nonsteroidal anti-inflammatory drug commonly used to reduce fever, pain, stiffness, and swelling from inflammation. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation. We will use Indomethacin to test COX as a potential mechanism explaining sex differences in CBF control. Indomethacin usage is IND exempt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 MG/50 MG
Description: Indomethacin is a nonsteroidal anti-inflammatory drug commonly used to reduce fever, pain, stiffness, and swelling from inflammation. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation. We will use Indomethacin to test COX as a potential mechanism explaining sex differences in CBF control. Indomethacin usage is IND exempt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Lactose
Description: Subjects will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit. Placebo usage is IND exempt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Lactose
Description: Subjects will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit. Placebo usage is IND exempt.
Study: NCT06613464

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosis confirmation
Description: The patients diagnoses will be confirmed though imaging methods like computed tomography chest x-ray and anamnesis
Study: NCT06613425

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined platelets
Description: 1 therapeutic dose combined platelet contained no less than 2.5 ×10\^11 platelets as a quality standard.
Study: NCT06609850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation (radiofrequency ablation, microwave ablation, cryoablation), ablation followed TACE within 6-8 weeks and Lenvatinib continued. Percutaneous ablation was performed by ultrasound or CT. The ablation success is evaluated by achieving an ablative margin of 0.5 cm or more than the tumor size.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinb
Description: Lenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinb
Description: Lenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day )
Study: NCT06421831

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GC101
Description: Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
Study: NCT05878795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WET-SP
Description: WET-SP will consist of 5 treatment sessions; the first session lasting about one hour and each subsequent session lasting approximately 45 minutes. Each session will include a 30-minute written exposure exercise. The participant will be given general instructions for completing the narrative writings and specific instructions for completing the first session. Participants will be instructed to write about the same suicidal crisis during each session. The therapist will emphasize the importance of delving into their deepest emotions surrounding the suicidal crisis as well as the importance of writing detailed information about the crisis. Following writing, the therapist and the participant will process the writing experience. Subsequent sessions involve the therapist iteratively providing feedback to the patient regarding their writing from the previous session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: TAU includes initial psychiatric stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily throughout the duration of hospitalization and have structured times for psychoeducation groups, case management, medication management, hygiene, and meals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: TAU includes initial psychiatric stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily throughout the duration of hospitalization and have structured times for psychoeducation groups, case management, medication management, hygiene, and meals.
Study: NCT05720104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard oral hygiene instructions
Description: Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene instructions
Description: Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
Study: NCT06498479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: HS-20093 will be administered as an IV infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan will be administered per drug label.
Study: NCT06554821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will receive rosuvastatin (dose 1 or dose 2) orally as a single dose on Day 1 in Period 1 and Day 6 in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will receive rosuvastatin (dose 1 or dose 2) orally as a single dose on Day 1 in Period 1 and Day 6 in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Participants in each arm will receive ticagrelor 90 mg orally BID from Day 6 to Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Participants in each arm will receive ticagrelor 90 mg orally BID from Day 6 to Day 10.
Study: NCT06598852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TPVB group
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB Group received thoracic paravertebral nerve block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESPB group
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ESPB Group received erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TPVB combined ESPB group
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB combined ESPB group received thoracic paravertebral block combined with erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICNB group
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ICNB Group received intercostal nerve block for postoperative analgesia.
Study: NCT06614348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate eye drop group
Description: Patients receive prednisolone acetate eye drops 4 times per 30min within 2 hours before cataract surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium hyaluronate eye drops
Description: Patients receive sodium hyaluronate eye drops 4 times per 30min within 2 hours before cataract surgery
Study: NCT04968574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taladegib
Description: hedgehog pathway inhibitor dosed once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical tablets to the experimental arm with no active ingredient
Study: NCT06688734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inital water seal
Description: After chest tube placement, the chest tube will be placed to 20cm H2O of suction for 1 minute to evacuate all pneumothorax. After this, the chest tube will be placed to water seal, defined as the water seal chamber on the chest tube drainage system being filled up to the 2cm line and not on suction. All other management decisions related to the chest tube will be left to the providers.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initial suction
Description: After chest tube placement, the suction group will have their chest tube placed to 20cm H2O of suction delivered by the chest tube drainage suction. All other management decisions related to the chest tube will be left to the providers.